Neurocrine Bio. (NBIX) PT Raised to $158 at Citi
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall St tumbles on tech selloff as concerns about hawkish Fed, AI spending mount
- SpaceX extends losses after $600 billion wipeout, tech stocks slide again
- Oil steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Neurocrine Bio. (NBIX) PT Raised to $163 at Wedbush
August 1, 2024 12:16 PM EDTWedbush analyst Laura Chico raised the price target on Neurocrine Bio. (NASDAQ: NBIX) to $163.00 (from $152.00) while maintaining a Outperform rating.... More
Neurocrine Biosciences (NBIX) Tops Q2 EPS by 50c
August 1, 2024 7:09 AM EDTNeurocrine Biosciences (NASDAQ: NBIX) reported Q2 EPS of $1.63, $0.50 better than the analyst estimate of $1.13. Revenue for the quarter came in at $580 million versus the consensus estimate of $547.1 million.
For earnings history and earnings-related data on Neurocrine Biosciences (NBIX) click here.
... More